Codis

In April 2026, Codis in Haverhill, Suffolk received an award from the Life Sciences Innovative Manufacturing Fund (LSIMF) to expand its spray-drying manufacturing capability, focused on drug candidates for cancer and neurodegenerative diseases. The project is expected to create 29 jobs at the Haverhill site, making it one of the more concrete job-creation outcomes in the four-site £80m+ geographic-diversification package announced by DSIT on 14 April 2026.

Codeis is a UK contract development and manufacturing organisation (CDMO) specialising in spray-drying technology. Spray-drying converts liquid drug solutions into stable dry powders, enhancing the bioavailability of poorly water-soluble active pharmaceutical ingredients — a common barrier in oncology and neurology drug development. The technique is applicable across a wide range of dosage forms and is used by pharmaceutical partners that lack in-house drying capacity at GMP scale.

Spray-drying capability sits at a critical enabling layer for many advanced oncology and neurodegenerative drug pipelines; the shortage of UK capacity in this technology has historically pushed development work to continental European CDMOs. Codis's LSIMF-backed expansion reflects the government's stated strategy of anchoring specialist pharmaceutical manufacturing capabilities in regions outside the Golden Triangle, with Suffolk joining Devon, Birmingham, and South Wales as a site of deliberate industrial investment in 2026.